Related Experiment Videos
[Prophylaxis and therapy of fungal infections in oncology]
U Schuler1, M Mölle, G Ehninger
1Medizinische Klinik I, Universitätsklinikum, Dresden, FR Germany.
Abstract:
The observation of a considerable incidence of fungal infections in oncology patients has promoted a large number of studies both on prophylaxis and treatment in this patient group. Trials using triazoles, especially fluconazole, have shown effect in preventing fungal infections. In neutropenic patients, their role in therapy still remains less clear. Amphotericin B is the drug of choice for most life-threatening infections. With this drug, efforts concentrate upon the amelioration of side effects by sodium loading, administration in lipid emulsions or liposomes. The use of AMB as low-dose systemic prophylaxis or by inhalation needs further study.
Insights
Fungal infections are common in oncology patients. While fluconazole helps prevent infections, its role in treating neutropenic patients needs more research. Amphotericin B remains crucial for severe infections, with ongoing efforts to reduce its side effects.
Area of Science:
- Medical Mycology
- Oncology
- Infectious Diseases
Context:
- Fungal infections pose a significant threat to oncology patients, necessitating research into effective prophylaxis and treatment strategies.
- Antifungal prophylaxis, particularly with triazoles like fluconazole, has demonstrated efficacy in preventing fungal infections in this vulnerable population.
- The therapeutic role of fluconazole in neutropenic patients remains less defined, highlighting a gap in current treatment protocols.
Purpose:
- To review current strategies for fungal infection prophylaxis and treatment in oncology patients.
- To evaluate the efficacy of triazoles, specifically fluconazole, in preventing fungal infections.
- To discuss the established role of Amphotericin B in treating life-threatening fungal infections and ongoing efforts to mitigate its adverse effects.
Summary:
- Fungal infections are prevalent in cancer patients, prompting extensive research into prevention and treatment.
- Fluconazole has shown promise in preventing fungal infections, but its therapeutic use in neutropenic patients requires further investigation.
- Amphotericin B is the primary treatment for severe fungal infections, with research focused on reducing side effects through methods like lipid formulations.
- Further studies are needed to explore the potential of low-dose Amphotericin B for systemic prophylaxis or inhalation therapy.
Impact:
- Provides an overview of current antifungal strategies in oncology.
- Highlights the need for further research into fluconazole's efficacy in neutropenic patients.
- Informs clinical practice regarding the use of Amphotericin B and potential new therapeutic avenues.